Akeso Reports Positive Phase III Results for Ivonescimab in Lung Cancer
Akeso announced that its Phase III HARMONi-6 trial showed ivonescimab plus chemotherapy significantly prolonged progression-free survival in advanced squamous non-small cell lung cancer compared to tislelizumab plus chemotherapy.